NDANASALSPRAY, METERED
Approved
Jun 2021
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASTEPRO ALLERGY is an azelastine hydrochloride nasal spray approved in 2021 for allergic rhinitis symptoms. It is a selective H1-receptor antagonist delivered via metered nasal spray that rapidly reduces itching, sneezing, and nasal congestion. The drug addresses seasonal and perennial allergic rhinitis in patients seeking non-systemic allergy relief.
LOE Approaching1.7 years to LOE
Moderate competitive pressure (15 competitors) in a crowded allergy market signals defensive positioning; brand team focus likely shifting toward retention and differentiation before LOE.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
Started Mar 2011
347 enrolled
Perennial Allergic Rhinitis
Why This Matters for Your Career
Worked on ASTEPRO ALLERGY at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.